Stem Cell Therapy for Epidermolysis Bullosa—Does It Work? Katsuto Tamai, Jouni Uitto  Journal of Investigative Dermatology  Volume 136, Issue 11, Pages 2119-2121 (November 2016) DOI: 10.1016/j.jid.2016.07.004 Copyright © 2016 The Authors Terms and Conditions

Figure 1 Cross-talk between necrotic skin and bone marrow-derived mesenchymal stem cells leading to suppression of inflammation and induction of tissue regeneration. Release of HMGB1 from necrotic epithelial cells signals to bone marrow-derived PDGFRα+/CXCR4+ cells, leading to their migration to circulation and subsequent homing to the damaged skin through the stromal cell-derived factor 1α (SDF-1α)/CXCR4 axis. Tissue regeneration may involve mesenchymal and epithelial differentiation of bone marrow-derived stem cells in RDEB skin. HIF, hypoxia-inducible factor; H/S, HMGB1/SDF-1α; PDGFRα, platelet-derived growth factor receptor α; RDEB, recessive dystrophic epidermolysis bullosa. Journal of Investigative Dermatology 2016 136, 2119-2121DOI: (10.1016/j.jid.2016.07.004) Copyright © 2016 The Authors Terms and Conditions